Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: gene editing based therapeutics - Casebia Therapeutics

Drug Profile

Research programme: gene editing based therapeutics - Casebia Therapeutics

Alternative Names: CRISPR/Cas9 gene editing therapies - Bayer-CRISPR Therapeutics

Latest Information Update: 09 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Casebia Therapeutics
  • Class Antihaemorrhagics; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene modulators; Gene transference; Immunogenetic modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Research Cancer; Haemophilia A; Retinitis pigmentosa
  • No development reported Blindness; Congenital heart defects; Severe combined immunodeficiency

Most Recent Events

  • 09 May 2022 Drug is still in research phase for Haemophilia A in USA
  • 28 Apr 2022 CRISPR Therapeutics terminates Joint Venture Agreement for gene editing based therapeutics with Bayer
  • 28 Feb 2022 The US Patent and Trademark Office issues decision in favor of Broad Institute for interference claim for patent related to CRISPR-Cas9 genome editing technology in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top